Search results

1. ESMO 2023 – BioNTech still has work to do on Claudin6

   ESMO 2023 – BioNTech still has work to do on Claudin6 … trial +/- CARVac in CLDN6+ solid tumours (NCT04503278) ESMO 2023 with automated manufacturing: 45% ORR (17/38) …

   
    

   Madeleine Armstrong
    
   - 07/10/2024 - 10:07

2. ESMO 2023 – Nectin-4 in focus

   ESMO 2023 – Nectin-4 in focus Quick …

   
    

   Jacob Plieth
    
   - 10/24/2023 - 14:58

3. ESMO 2023 – how datopotamab's lung side effects are graded

   ESMO 2023 – how datopotamab's lung side effects are graded …

   
    

   Jacob Plieth
    
   - 10/24/2023 - 14:57

4. ESMO 2023 – red flags for PSMAfore

   ESMO 2023 – red flags for PSMAfore Full …

   
    

   Madeleine Armstrong
    
   - 10/30/2023 - 16:21

5. ESMO 2023 – Biontech’s Neon buy fails to shine

   ESMO 2023 – Biontech’s Neon buy fails to shine …

   
    

   Madeleine Armstrong
    
   - 10/23/2023 - 15:38

6. ESMO 2023 – regulators come under fire for Retevmo trial requirements

   ESMO 2023 – regulators come under fire for Retevmo trial …

   
    

   Madeleine Armstrong
    
   - 10/23/2023 - 15:37

7. ESMO 2023 – more hope for a new Car-T target

   ESMO 2023 – more hope for a new Car-T target … – 1 PR (KRASm tumour) in 9 patients reported at ESMO 2023 PF-07062119 T-cell engager Pfizer …

   
    

   Jacob Plieth
    
   - 10/23/2023 - 15:38

8. ESMO 2023 – the colorectal KRAS pipeline swells again

   ESMO 2023 – the colorectal KRAS pipeline swells again … TRAEs 36% 30% 13% 16% 41% Source: ESMO 2023, AACR 2023 & ESMO 2022. …

   
    

   Madeleine Armstrong
    
   - 10/23/2023 - 14:44

9. ESMO 2023 – Padcev hits its home run

   ESMO 2023 – Padcev hits its home run …

   
    

   Jacob Plieth
    
   - 10/27/2023 - 17:39

10. ESMO 2023 – Daiichi shows why Merck paid $1.5bn for CDH6

    ESMO 2023 – Daiichi shows why Merck paid $1.5bn for CDH6 …

    
     

    Jacob Plieth
     
    - 10/23/2023 - 15:15